Joe Nocera, Columnist

MiMedx Has Changed, But Its Critics Haven’t

Doctors who use its products say it’s because they work. New investors have high expectations. So why haven’t the shorts let go?

August 22, 2019 at 4:35 PM UTC

By Joe Nocera

Joe Nocera is a former Bloomberg Opinion columnist. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. He is the host and writer of the Bloomberg-Wondery podcast "The Shrink Next Door."

Maybe EpiFix can help.
Source: BSIP/Universal Images Group Editorial/Getty Images

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

This is the second of two columns about MiMedx and the short-sellers. Read the first here.

Most of the time, Eiad Asbahi, the 40-year-old founder of Prescience Point Capital Management, is a short-seller.